The pharmaceutical industry remains a hotbed of innovation, fueled by the evolution of new therapeutic paradigms, the magnitude of unmet needs, and the growing importance of technologies such as pharmacogenomics, digital therapeutics and artificial intelligence. . More than 633,000 patents have been filed and granted in the pharmaceutical industry in the last three years alone, according to GlobalData’s Immuno-Oncology in Pharmaceuticals report: Monoclonal Antibody Conjugates for Cancer Treatment.
According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyze the innovation strength of the pharmaceutical industry, there are 110 areas of innovation that will shape the industry’s future.
Monoclonal antibody conjugates for cancer therapy are a key area of innovation in immuno-oncology
The main purpose of antibody-drug conjugates (ADCs) is to enhance the efficacy of anticancer drugs by minimizing systemic drug distribution and targeting specific cells. ADCs are a class of drugs consisting of a monoclonal antibody conjugated to a cytotoxic drug via a chemical linker. Developing an effective ADC for cancer therapy requires selecting an appropriate target, developing a monoclonal antibody against the target, and then conjugating the antibody to a cytotoxic agent to selectively deliver a toxic payload. I have.
GlobalData’s analysis also reveals the companies at the forefront of each innovation area and assesses the potential reach and impact of their patent activity across various applications and geographies. According to GlobalData, there are over 90 companies, including technology vendors, established pharmaceutical companies, and start-ups, engaged in the development and application of monoclonal antibody conjugates for cancer therapy.
Major Players in Monoclonal Antibody Conjugates for Cancer Therapeutics – Disruptive Innovation in Pharmaceuticals industry
“Application Diversity” measures the number of different applications identified for each relevant patent and broadly categorizes companies into “niche” or “diverse” innovators.
“Geographic coverage” refers to the number of different countries in which each patent is registered, reflecting the breadth of intended geographic application, from “global” to “local.”
Patent volume related to cancer therapeutic monoclonal antibody conjugates
Source: GlobalData Patent Analytics
F. Hoffmann-La Roche is the lead patent applicant for monoclonal antibody conjugates for cancer therapy. F. Hoffmann-La Roche is a biotechnology company that develops pharmaceuticals and diagnostics for the treatment of major diseases. We offer medicines to treat cancer, other autoimmune diseases, central nervous system disorders, ophthalmic disorders, infectious diseases and respiratory diseases. Roche has several monoclonal antibody conjugates, some approved and some in development. Kadcyla, one of his two over-the-counter medicines, is manufactured by Roche.
In terms of application diversity, AusHealth comes first, followed by Epic Sciences and McSAF. In terms of geographic reach, Astellas Pharma is the top, with Tron and Eisai at number two and him at number three respectively.
To better understand the key themes and technologies disrupting the pharmaceutical industry, visit GlobalData’s latest Thematic Research Reports on Pharmaceuticals.
Subscribe to our newsletter
Industry-leading news, data and analysis delivered to your inbox
Subscribe
GlobalData, a leading provider of industry intelligence, provided the underlying data, research, and analysis used to create this article.
GlobalData’s Patent Analytics tracks patent filings and grants from offices around the world. We use text analysis and formal patent taxonomies to group patents into key thematic areas and associate them with specific companies in the world’s largest industries.